Pfizer Venture Investments and the Roche Venture Fund, the corporate venturing units of drugs companies Pfizer and Roche, are among the investors in Canada-based analytical instrument manufacturer DVS Sciences’ $14.6m series A round.
Roche and Pfizer were joined in the round by US-based venture capital firms 5AM Ventures and Mohr Davidow, along with the Ontario Institute for Cancer Research.
DVS Sciences, which was founded in 2004 as a spin-off from the University of Toronto, will use the proceeds to commercially develop its single cell analysis system.
Andrew Schwab, managing partner at 5AM Ventures, who joined DVS’s board along with Willaim (Bill) Burkoth, senior director of Pfizer Ventures, said: "DVS Sciences has made great strides in demonstrating the significant demand for quantitative, highly multiparametric biomarker assays performed in single cells and we are pleased to be part of this significant series A financing. The company is well positioned for high growth and to expand the cellular analysis marketplace."